Groundbreaking Antifungal Therapies to be Developed at Alderley Park as F2G Joins Innovation Campus

F2G Ltd, a leading developer of novel antifungal therapies, has chosen Bruntwood SciTech’s premier life science and innovation campus, Alderley Park, as its new UK headquarters, consolidating its existing operations in Eccles and MediaCity into one purpose-designed, specialist lab space.

The move sees F2G take almost 3,000 sq ft of high-specification lab space in the Mereside site at Alderley Park, in a newly refurbished – and now fully let – block for growing life science businesses. The consolidation supports the company’s accelerated development and regulatory plans following completion of a $100 million round of fundraising raise in late 2024. The company was visited last week at Alderley Park by Chief Medical Officer Professor Sir Chris Whitty to discuss the fungal disease landscape and barriers to antifungal drug research and development in the UK. 

Being based at the leading science and innovation campus, owned and operated by Bruntwood SciTech - a joint venture between Bruntwood, L&G, and Greater Manchester Pension Fund and the UK’s largest property provider dedicated to the growth of tech, science and innovation sectors – will help F2G to advance its late-stage development of antifungal therapies — aimed at tackling rare and resistant infections — within a highly connected and collaborative environment.

F2G will join the ranks of Alderley Park’s impressive roster of life science innovators and technology-focused firms, and will gain access to opportunities for collaboration with forward-thinking companies such as Medicines Discovery Catapult, CellCentric, Globachem Discovery, Evotec, global software developers SAP, and fellow recent arrivals Revvity. Alongside established innovators, they will also benefit from the ability to partner with companies who are part of the Alderley Park Life Sciences Accelerator and Female Founders Incubator. F2G not only becomes part of the Alderley Park like-minded community, but has access to Bruntwood SciTech’s UK wide customer network of 1,100 innovation-led companies to support further collaboration.

In addition to specialist lab facilities, F2G will have the opportunity to access Bruntwood SciTech’s shared science services and coworking lab at Alderley Park, alongside a full range of leading amenities and green spaces, including meeting rooms and breakout spaces, cafes, on-site gym, sports pitches, state-of-the-art cycle and shower hub, The Churchill Tree pub, and 232-seat auditorium. Bruntwood SciTech also offers businesses the opportunity to strengthen their connectivity to the NHS and the region’s highly-skilled talent and research through their joint venture partnerships with Manchester University NHS Foundation Trust (MFT) and The University of Manchester, gaining direct access to collaborations, sample supplies, and introductions to clinicians.

Kath Mackay, Chief Scientific Officer for Bruntwood SciTech, said: “F2G’s decision to establish its UK base at Alderley Park is a strong endorsement of what the campus offers companies developing novel therapies . At a critical point in their growth journey, F2G recognised the value of consolidating their team within a campus that brings together state-of-the-art infrastructure, shared science services, a vibrant scientific community of collaborators and an established talent pool in one place.

“The new facility will give F2G the technical flexibility it needs to advance its clinical and preclinical development. As they work to advance first-in-class antifungals with the potential to transform outcomes for patients, being based at Alderley Park will support both development and future commercial readiness. It’s a place where pioneering science can move at pace, backed by infrastructure and an ecosystem that’s been purpose-built for exactly this kind of work.

“Being fully-let just months after completion, the latest workspace block we have refurbed at Alderley Park underlines the level of demand for lab-ready, growth-focused environments in the North West. With more than 250 science and tech businesses and 4,000 people now based at Alderley Park — from early-stage innovators to global leaders — F2G is joining a community with the energy, expertise and ambition to help accelerate healthcare breakthroughs.”

Dr Mike Birch, Chief Operating Officer, F2G, said: “We are delighted to join the Alderley Park family. Relocating our laboratories and offices to a brand new, modern facility is very exciting and we look forward to discovering and developing more novel therapies here. Being located on the Alderley Park campus allows us to consolidate working relationships with current vendors and to begin new collaborations with innovative partners. As we grow, locating to Alderley Park will enhance our ability to recruit talent and provide a fantastic working environment.”